• JPM 2022: Illumina posts new sales records, lays out long-read chemistry plans

    8 days ago - By San Diego Biotechnology

    JPM 2022: Illumina posts new sales records, lays out long-read chemistry plans chale
    Mon, 01/10/2022 - 17:34
    Read more ...

     

  • JPM 2022: Bristol Myers buoys cell therapy interests with $3B biobucks deal with Bayer-backed Century, $70M upfront to ArsenalBio

    8 days ago - By Fierce Biotech

    JPM 2022: Bristol Myers buoys cell therapy interests with $3B biobucks deal with Bayer-backed Century, $70M upfront to ArsenalBio klahucik
    Mon, 01/10/2022 - 08:19
    Read more ...

     

  • JPM 2022: Moderna finds Carisma's macrophage tech compelling enough for $45M cancer research deal

    8 days ago - By Fierce Biotech

    JPM 2022: Moderna finds Carisma's macrophage tech compelling enough for $45M cancer research deal aarmstrong
    Mon, 01/10/2022 - 09:33
    Read more ...

     

  • JPM 2022: Sarepta projects Duchenne muscular gene therapy will go to FDA next year, sees shares crash 15%

    8 days ago - By Fierce Biotech

    JPM 2022: Sarepta projects Duchenne muscular gene therapy will go to FDA next year, sees shares crash 15% klahucik
    Mon, 01/10/2022 - 11:50
    Read more ...